AR013063A1 - Formula de vacuna aviaria, su utilizacion y kit de vacunacion - Google Patents
Formula de vacuna aviaria, su utilizacion y kit de vacunacionInfo
- Publication number
- AR013063A1 AR013063A1 ARP970103112A ARP970103112A AR013063A1 AR 013063 A1 AR013063 A1 AR 013063A1 AR P970103112 A ARP970103112 A AR P970103112A AR P970103112 A ARP970103112 A AR P970103112A AR 013063 A1 AR013063 A1 AR 013063A1
- Authority
- AR
- Argentina
- Prior art keywords
- virus
- disease virus
- aviary
- vaccine formula
- disease
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 3
- 241000271566 Aves Species 0.000 abstract 2
- 241000711404 Avian avulavirus 1 Species 0.000 abstract 2
- 241000711450 Infectious bronchitis virus Species 0.000 abstract 2
- 208000007502 anemia Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000002458 infectious effect Effects 0.000 abstract 2
- 239000013612 plasmid Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 abstract 1
- 208000006758 Marek Disease Diseases 0.000 abstract 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/255—Marek's disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
- C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/22011—Dicistroviridae
- C12N2770/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La formula de vacuna aviaria comprende al menos 3 valencias de vacuna polinucleotídica, cada una de las cuales comprende un plásmido integrante demanera de expresar in vivo en las células huésped un gen de una valencia de la patogeniaaviaria, estando elegidas estas valencias del grupo que comprendevirus de la enfermedad de Marek, virus de la enfermedad de Newcastle, virus de la enfermedad de Gumboro, virus de la bronquitis infecciosa, virus de laanemia infecciosa,comprendiendo los p lásmidos para cada valencia uno o varios de los genes elegidos del grupo que comprende gB y gD para el virus de laenfermedad de Marek, HN y F para el virus de la enfermedad de Newcastle, VP2 para el virus de la enfermedad deGumboro, S, M y N par a el virus de labronquitis infecciosa, C+ NS1 para el virus de la anemia infecciosa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9609339A FR2751225B1 (fr) | 1996-07-19 | 1996-07-19 | Formule de vaccin polynucleotidique aviaire |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR013063A1 true AR013063A1 (es) | 2000-12-13 |
Family
ID=9494451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970103112A AR013063A1 (es) | 1996-07-19 | 1997-07-11 | Formula de vacuna aviaria, su utilizacion y kit de vacunacion |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US6221362B1 (es) |
| EP (2) | EP0914442B1 (es) |
| JP (2) | JP2001503019A (es) |
| KR (1) | KR20000065258A (es) |
| CN (2) | CN1701788A (es) |
| AR (1) | AR013063A1 (es) |
| AU (1) | AU735184B2 (es) |
| BR (1) | BR9710495A (es) |
| CA (1) | CA2261343A1 (es) |
| CO (1) | CO4700304A1 (es) |
| DE (1) | DE69730839T2 (es) |
| ES (1) | ES2232876T3 (es) |
| FR (1) | FR2751225B1 (es) |
| HU (1) | HU224830B1 (es) |
| ID (1) | ID19475A (es) |
| MA (1) | MA24268A1 (es) |
| NZ (1) | NZ333779A (es) |
| TN (1) | TNSN97120A1 (es) |
| WO (1) | WO1998003659A1 (es) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751225B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
| ZA978434B (en) * | 1996-09-27 | 1998-03-26 | Akzo Nobel Nv | Inactivated vaccines. |
| US6468984B1 (en) * | 1999-06-08 | 2002-10-22 | Innovo Biotechnologies Ltd. | DNA vaccine for protecting an avian against infectious bursal disease virus |
| AU4606000A (en) * | 1999-06-10 | 2001-01-02 | Agricultural Research Council | Vaccine for newcastle disease virus |
| AR031405A1 (es) * | 2000-11-21 | 2003-09-24 | Wyeth Corp | Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo |
| FR2823222B1 (fr) | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
| IL145397A0 (en) * | 2001-09-12 | 2002-06-30 | Yissum Res Dev Co | Compositions and methods for treatment of cancer |
| US7615209B2 (en) | 2001-09-12 | 2009-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions of NDV and methods of use thereof for treatment of cancer |
| US7037506B2 (en) * | 2002-03-08 | 2006-05-02 | Schweltzer Chemical Corporation Ltd. | Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry |
| US7029681B2 (en) * | 2002-03-08 | 2006-04-18 | Schweitzer Chemical Corporation | Multiple and multivalent DNA vaccines in ovo |
| JP2005538343A (ja) * | 2002-04-12 | 2005-12-15 | イラリア・カプア | ノイラミニダーゼをコードする精製サブフラグメント、組み換えノイラミニダーゼ、及び動物予防におけるその使用 |
| NZ539299A (en) * | 2002-10-15 | 2006-12-22 | Wyeth Corp | Assay methods for detection of a virus in an avian tissue sample |
| EP2390352A1 (en) | 2003-03-18 | 2011-11-30 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| EP1689858B1 (en) | 2003-11-13 | 2013-05-15 | University Of Georgia Research Foundation, Inc. | Methods of characterizing infectious bursal disease virus |
| EP1718770B1 (en) | 2004-02-19 | 2011-05-25 | The Governors of the University of Alberta | Leptin promoter polymorphisms and uses thereof |
| SI1881845T1 (sl) | 2005-04-25 | 2010-06-30 | Merial Ltd | Cepiva proti virusu Nipah |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| DE102005040812A1 (de) * | 2005-08-27 | 2007-03-15 | Few Fahrzeugelektrikwerk Gmbh & Co. Kg | Elektrischer Anschluss sowie Verfahren zu dessen Verbindung mit der Scheibe eines Kraftfahrzeugs |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| EP3147296A1 (en) | 2005-11-14 | 2017-03-29 | Merial, Inc. | Gene therapy for renal failure |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| US20080274137A1 (en) * | 2007-05-02 | 2008-11-06 | Jean Christophe Francis Audonnet | DNA plasmids having improved expression and stability |
| HRP20130643T1 (hr) | 2007-05-02 | 2013-08-31 | Merial Limited | Dnk-plazmidi koji imaju poboljšanu ekspresiju i stabilnost |
| CN102046522A (zh) * | 2008-06-03 | 2011-05-04 | 旭硝子株式会社 | 核—壳粒子的制造方法、核—壳粒子、中空粒子的制造方法、涂料组合物及物品 |
| EP3168307B1 (en) | 2008-11-28 | 2020-07-15 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant avian influenza vaccine and uses thereof |
| KR101715418B1 (ko) | 2009-04-03 | 2017-03-10 | 메리얼 인코포레이티드 | 뉴캐슬 질환 바이러스-벡터를 이용한 조류 백신 |
| KR20120101572A (ko) | 2009-12-28 | 2012-09-13 | 메리얼 리미티드 | 재조합 ndv 항원 및 이의 용도 |
| US20130197612A1 (en) | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
| AU2011224188B2 (en) | 2010-03-12 | 2015-01-22 | Boehringer Ingelheim Animal Health USA Inc. | Bluetongue virus recombinant vaccines and uses thereof |
| WO2012030720A1 (en) | 2010-08-31 | 2012-03-08 | Merial Limited | Newcastle disease virus vectored herpesvirus vaccines |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| AU2012240240A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| AU2012240246A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| AU2012245395A1 (en) | 2011-04-20 | 2013-11-14 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
| AP2013007180A0 (en) | 2011-04-25 | 2013-10-31 | Advanced Bioscience Lab Inc | Truncated HIV envelope proteins (ENV), methods andcompositions related thereto |
| MX361804B (es) | 2011-05-27 | 2018-12-17 | Boehringer Ingelheim Animal Health Usa Inc | Vacunas genéticas contra el virus hendra y el virus nipah. |
| CA2837375C (en) | 2011-06-01 | 2019-07-16 | Merial Limited | Needle-free administration of prrsv vaccines |
| ES2626297T3 (es) | 2011-08-12 | 2017-07-24 | Merial, Inc. | Preservación asistida por vacío de productos biológicos, en particular de vacunas |
| CN105920598A (zh) * | 2011-11-30 | 2016-09-07 | 梅里亚有限公司 | 表达禽类病原体的抗原的重组hvt载体及其用途 |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| KR102087458B1 (ko) | 2012-02-14 | 2020-03-10 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 로타바이러스 아단위 백신 및 그의 제조 방법 및 용도 |
| CN104203271B (zh) | 2012-02-14 | 2017-08-25 | 梅里亚股份有限公司 | 表达狂犬病病毒和ox40蛋白的重组痘病毒载体及从其制造的疫苗 |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| CN104582724A (zh) | 2012-06-13 | 2015-04-29 | 梅里亚有限公司 | 重配btv和ahsv疫苗 |
| CN102719567A (zh) * | 2012-07-05 | 2012-10-10 | 广东温氏食品集团有限公司 | 禽传染性支气管炎病毒h120毒株的pcr检测引物及检测方法 |
| HK1216006A1 (zh) | 2013-03-12 | 2016-10-07 | Boehringer Ingelheim Animal Health USA Inc. | 反向遺傳學施馬倫貝格病毒疫苗組合物,和其使用方法 |
| CA2949682A1 (en) | 2014-05-19 | 2015-11-26 | Merial, Inc. | Method and device for conditional in ovo injection |
| IL241841B (en) * | 2014-09-30 | 2019-09-26 | Univ Free State | Production of proteins for human and animal health using yarrowia lipolytica |
| EP3215188A1 (en) | 2014-11-03 | 2017-09-13 | Merial, Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| CN104881148B (zh) * | 2015-05-15 | 2017-12-15 | 苏州达方电子有限公司 | 键盘及其控制方法 |
| NZ738957A (en) | 2015-06-23 | 2019-09-27 | Boehringer Ingelheim Animal Health Usa Inc | Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof |
| CA2996143A1 (en) | 2015-08-20 | 2017-02-23 | Merial, Inc. | Fcv recombinant vaccines and uses thereof |
| RU2710854C1 (ru) | 2015-09-29 | 2020-01-14 | Мериал, Инк. | Вакцины на основе вирусоподобных частиц (vlp) собачьего парвовируса (cpv) и их применение |
| ES2899230T3 (es) | 2015-11-23 | 2022-03-10 | Boehringer Ingelheim Animal Health Usa Inc | Proteínas de fusión de FMDV y E2 y usos de las mismas |
| TWI760322B (zh) | 2016-01-29 | 2022-04-11 | 美商百靈佳殷格翰動物保健美國有限公司 | 重組腺病毒載體裝載之fmdv疫苗及其用途 |
| CN107099513B (zh) * | 2017-06-22 | 2020-07-14 | 北京邦卓生物科技有限公司 | 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用 |
| CN111727053B (zh) * | 2018-01-26 | 2024-06-25 | 全国农业协同组合连合会 | 非人动物用抗原表面结合型脂质体疫苗 |
| CN110777122A (zh) * | 2019-10-21 | 2020-02-11 | 青岛易邦生物工程有限公司 | 一种表达ibdv的vp2蛋白的重组ⅰ型马立克氏病病毒 |
| CN115089700B (zh) * | 2022-05-25 | 2025-07-25 | 永州中古生物技术有限公司 | 一种抗β属冠状病毒的疫苗组合物及其应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0474676A4 (en) * | 1989-05-30 | 1993-02-24 | The Commonwealth Scientific And Industrial Research Organization | Production of ibdv vp2 in highly immunogenic form |
| JPH06509235A (ja) * | 1991-07-26 | 1994-10-20 | ヴァイロジェネティクス コーポレイション | 伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン |
| FR2697534A1 (fr) * | 1992-11-02 | 1994-05-06 | Rhone Merieux | Virus herpès de la dinde recombinant pour la réalisation de vaccin de la maladie de Gumboro, son procédé de préparation et vaccin obtenu. |
| EP0620277A1 (en) * | 1993-03-18 | 1994-10-19 | Merck & Co. Inc. | Nucleic acid pharmaceuticals |
| WO1994024268A1 (en) * | 1993-04-14 | 1994-10-27 | Arthur Webster Pty. Ltd. | Recombinant avian adenovirus vector |
| EP0740704A1 (en) * | 1994-01-27 | 1996-11-06 | University Of Massachusetts Medical Center | Immunization by inoculation of dna transcription unit |
| JPH08116976A (ja) * | 1994-10-20 | 1996-05-14 | Chemo Sero Therapeut Res Inst | 免疫用核酸調製物およびこれを用いた免疫方法 |
| US5736524A (en) * | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| FR2728794B1 (fr) * | 1994-12-30 | 1997-03-21 | Rhone Merieux | Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro |
| WO1996021034A1 (fr) * | 1994-12-30 | 1996-07-11 | Rhone Merieux | Vaccin vivant recombinant aviaire |
| FR2751225B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
| US5916879A (en) | 1996-11-12 | 1999-06-29 | St. Jude Children's Research Hospital | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof |
| US6468984B1 (en) * | 1999-06-08 | 2002-10-22 | Innovo Biotechnologies Ltd. | DNA vaccine for protecting an avian against infectious bursal disease virus |
-
1996
- 1996-07-19 FR FR9609339A patent/FR2751225B1/fr not_active Expired - Lifetime
-
1997
- 1997-07-11 AR ARP970103112A patent/AR013063A1/es unknown
- 1997-07-15 TN TNTNSN97120A patent/TNSN97120A1/fr unknown
- 1997-07-16 AU AU37736/97A patent/AU735184B2/en not_active Expired
- 1997-07-16 HU HU9902790A patent/HU224830B1/hu unknown
- 1997-07-16 BR BR9710495A patent/BR9710495A/pt not_active Application Discontinuation
- 1997-07-16 CN CNA2005100669793A patent/CN1701788A/zh active Pending
- 1997-07-16 CA CA002261343A patent/CA2261343A1/fr not_active Abandoned
- 1997-07-16 CN CN97196561A patent/CN1225685A/zh active Pending
- 1997-07-16 WO PCT/FR1997/001326 patent/WO1998003659A1/fr not_active Ceased
- 1997-07-16 EP EP97934579A patent/EP0914442B1/fr not_active Expired - Lifetime
- 1997-07-16 ES ES97934579T patent/ES2232876T3/es not_active Expired - Lifetime
- 1997-07-16 DE DE69730839T patent/DE69730839T2/de not_active Expired - Lifetime
- 1997-07-16 EP EP04021994A patent/EP1523992A1/fr not_active Withdrawn
- 1997-07-16 NZ NZ333779A patent/NZ333779A/xx unknown
- 1997-07-16 KR KR1019980710910A patent/KR20000065258A/ko not_active Ceased
- 1997-07-16 JP JP10506638A patent/JP2001503019A/ja active Pending
- 1997-07-16 ID IDP972482A patent/ID19475A/id unknown
- 1997-07-16 MA MA24715A patent/MA24268A1/fr unknown
- 1997-07-18 CO CO97040980A patent/CO4700304A1/es unknown
-
1999
- 1999-01-15 US US09/232,479 patent/US6221362B1/en not_active Expired - Lifetime
-
2001
- 2001-02-16 US US09/784,990 patent/US6464984B2/en not_active Expired - Lifetime
-
2002
- 2002-08-28 US US10/229,412 patent/US20030124145A1/en not_active Abandoned
-
2008
- 2008-10-31 JP JP2008282541A patent/JP2009149608A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ID19475A (id) | 1998-07-16 |
| US6221362B1 (en) | 2001-04-24 |
| HU224830B1 (en) | 2006-02-28 |
| MA24268A1 (fr) | 1998-04-01 |
| AU3773697A (en) | 1998-02-10 |
| CO4700304A1 (es) | 1998-12-29 |
| FR2751225B1 (fr) | 1998-11-27 |
| BR9710495A (pt) | 1999-08-17 |
| US20020037292A1 (en) | 2002-03-28 |
| WO1998003659A1 (fr) | 1998-01-29 |
| US6464984B2 (en) | 2002-10-15 |
| ES2232876T3 (es) | 2005-06-01 |
| EP0914442B1 (fr) | 2004-09-22 |
| EP0914442A1 (fr) | 1999-05-12 |
| EP1523992A1 (fr) | 2005-04-20 |
| CA2261343A1 (fr) | 1998-01-29 |
| HUP9902790A2 (hu) | 1999-12-28 |
| JP2009149608A (ja) | 2009-07-09 |
| TNSN97120A1 (fr) | 2005-03-15 |
| CN1701788A (zh) | 2005-11-30 |
| JP2001503019A (ja) | 2001-03-06 |
| AU735184B2 (en) | 2001-07-05 |
| NZ333779A (en) | 2000-07-28 |
| FR2751225A1 (fr) | 1998-01-23 |
| KR20000065258A (ko) | 2000-11-06 |
| CN1225685A (zh) | 1999-08-11 |
| DE69730839D1 (de) | 2004-10-28 |
| US20030124145A1 (en) | 2003-07-03 |
| HUP9902790A3 (en) | 2000-03-28 |
| DE69730839T2 (de) | 2005-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR013063A1 (es) | Formula de vacuna aviaria, su utilizacion y kit de vacunacion | |
| AR034997A1 (es) | Formula de vacuna contra las patogenias de los canidos, utilizacion de uno o de varios plasmidos, y kit de vacunacion | |
| AR007861A1 (es) | Formula de vacuna para gatos, su utilizacion y kit de vacunacion | |
| AR007864A1 (es) | Formula de vacuna porcina, su utilizacion y kit de vacunacion que la contiene. | |
| CO4700306A1 (es) | Formula de vacuna plinucleotidica particularmente contra la patologia respiratoria de bovinos | |
| AR059828A2 (es) | Formula de vacuna para equidos, su utilizacion y kit de vacunacion | |
| Singh et al. | Re-emerging fowlpox: evaluation of isolates from vaccinated flocks | |
| García et al. | Commercial vaccines and vaccination strategies against infectious laryngotracheitis: what we have learned and knowledge gaps that remain | |
| PE52599A1 (es) | Vacuna viva recombinante aviaria, que comprende como vector el virus de la laringotraqueitis infecciosa | |
| Cavanagh et al. | Coronaviruses from pheasants (Phasianus colchicus) are genetically closely related to coronaviruses of domestic fowl (infectious bronchitis virus) and turkeys | |
| Perozo et al. | Efficacy of single dose recombinant herpesvirus of turkey infectious bursal disease virus (IBDV) vaccination against a variant IBDV strain | |
| ES2636464T5 (en) | Multivalent recombinant avian herpes viruses and vaccines for immunizing avian species | |
| A. Cook et al. | Infectious bronchitis virus vaccine interferes with the replication of avian pneumovirus vaccine in domestic fowl | |
| RU2019136150A (ru) | Вакцины против рекомбинантного герпесвируса gallid 3, кодирующие гетерологичные антигены птичьего патогена | |
| RU2019102170A (ru) | Вирус утиного энтерита и его применение | |
| RU2018103145A (ru) | Вирус утиного энтерита и его применение | |
| Pantin-Jackwood et al. | Efficacy of a recombinant turkey herpesvirus H5 vaccine against challenge with H5N1 clades 1.1. 2 and 2.3. 2.1 highly pathogenic avian influenza viruses in domestic ducks (Anas platyrhynchos domesticus) | |
| Han et al. | Efficacy of live virus vaccines against infectious laryngotracheitis assessed by polymerase chain reaction–restriction fragment length polymorphism | |
| RU2017130233A (ru) | Рекомбинантные вирусы mdv1 и их применение | |
| ECSP972183A (es) | Formula de vacuna polinucleotidica aviaria | |
| BR0102322A (pt) | Vìrus de uma cepa de vìrus de doença bursal infecciosa, vacina contra doença bursal infecciosa, métodos para a preparação do vìrus, e da vacina, e, uso do vìrus | |
| Okino et al. | Rapid detection and differentiation of avian infectious bronchitis virus: an application of Mass genotype by melting temperature analysis in RT-qPCR using SYBR Green I | |
| RU99103126A (ru) | Формула полинуклеотидной вакцины для птиц | |
| Wood et al. | Massachusetts live vaccination protects against a novel infectious bronchitis virus S1 genotype DMV/5642/06 | |
| ECSP972164A (es) | Vacunas de uso aviario a base de virus de laringotraqueitis infecciosa |